Dihexa is one of five compounds the FDA has scheduled for a second Pharmacy Compounding Advisory Committee review expected by February 2027. It's marketed online mainly as a "nootropic," a substance claimed to enhance memory or cognitive function, and it has one of the thinner human evidence bases of any compound this site has covered.
What It Is
Dihexa (chemical name N-hexanoic-Tyr-Ile-(6) aminohexanoic amide) is a small peptide-derived molecule developed from research into angiotensin IV, a fragment of the angiotensin hormone system best known for its role in blood pressure regulation. Researchers at Washington State University originally designed dihexa as a tool to study a growth-factor signaling pathway (the HGF/c-Met pathway) involved in the formation and strengthening of connections between neurons, a process called synaptogenesis. It was developed as a laboratory research compound intended to probe that biology, not as a drug candidate moving through a clinical development program.
What the Research Shows
The published research on dihexa is almost entirely preclinical: rodent studies examining its effects on synaptogenesis, spatial memory tasks in aged or cognitively impaired rats, and its underlying receptor pharmacology. Some of that early rodent work reported it as unusually potent, at least in the animal models used, at promoting the kind of neural connectivity changes associated with memory formation, which is part of why the compound attracted attention in nootropic communities online. What doesn't exist is any registered human clinical trial. There is no data on how dihexa behaves in the human body, what an appropriate or safe human dose might be, or whether the cognitive effects seen in rodent models translate to humans at all, a gap this site's guide on animal-versus-human evidence explains applies broadly across the peptide space, not just to dihexa specifically.
Regulatory Status
Dihexa is not an FDA-approved drug and has never been evaluated by the FDA for safety or efficacy in humans. It's currently marketed almost exclusively as a "research chemical," typically labeled explicitly "not for human consumption," a labeling category this site's guide on research-use-only products explains has real legal significance. It is included in the FDA's upcoming 2027 advisory panel review of Category 2 bulk substances, alongside GHK-Cu, Melanotan II, LL-37, and PEG-MGF, meaning its compounding status is under active regulatory review, though no determination has been made.
Safety Considerations
Because dihexa has never been through human safety testing, there is no established human side-effect profile, no verified safe dosing range, and no long-term safety data of any kind. It is typically sold in oral or nasal-spray formats through the same unregulated research-chemical marketplace as other compounds discussed on this site, which introduces additional risk from inconsistent purity, concentration, and labeling accuracy independent of the compound's own unknowns. Claims about cognitive benefits in humans are, at this point, extrapolations from animal data rather than demonstrated human effects.
The Bottom Line
Dihexa is a real research compound with a genuinely interesting mechanism of interest to neuroscience, but the leap from "promising in aged rats" to "safe and effective cognitive enhancer in humans" has not been tested, let alone confirmed, in a single published human trial. Its scheduled place in the FDA's 2027 peptide advisory review reflects the agency's broader effort to evaluate compounds like this for compounding eligibility, not a judgment about whether it works or is safe in people. Anyone interested in cognitive health should raise the topic with a licensed physician rather than relying on rodent-study extrapolations or online nootropic marketing.